奥拉帕利维持治疗新诊断BRCA突变晚期卵巢癌:SOLO1亚组分析
SOLO1亚组分析评估新诊断BRCA1/2突变晚期卵巢癌患者维持奥拉帕利(300mg每日两次)的PFS获益,按铂类化疗后反应、手术类型、术后残存病灶及BRCA突变类型分层。结果显示各亚组均获益,总体风险降低与主研究一致。
要点
- 无论手术类型、化疗反应或BRCA突变类型,奥拉帕利维持治疗均显著改善PFS。
- 初始手术与间歇手术患者疾病进展或死亡风险分别降低69%和63%。
- BRCA2突变者风险降低80%,BRCA1突变者降低59%。
核心结论
- 新诊断BRCA突变晚期卵巢癌患者从奥拉帕利维持治疗中获益,不受基线手术结局、化疗反应或BRCA突变类型影响。
研究设计与样本
- SOLO1研究的预设亚组分析,比较奥拉帕利(300mg每日两次)与安慰剂维持治疗,按临床反应、手术类型、术后残存病灶及BRCA突变状态分层。
主要发现
- 初始手术或间歇手术患者疾病进展或死亡风险分别降低69%(HR 0.31;95%CI 0.21-0.46)和63%(HR 0.37;95%CI 0.24-0.58)。
- 术后有残存病灶或无残存病灶患者风险分别降低56%(HR 0.44;95%CI 0.25-0.77)和67%(HR 0.33;95%CI 0.23-0.46)。
- 基线临床完全缓解或部分缓解患者风险分别降低66%(HR 0.34;95%CI 0.24-0.47)和69%(HR 0.31;95%CI 0.18-0.52)。
- BRCA1突变和BRCA2突变患者风险分别降低59%(HR 0.41;95%CI 0.30-0.56)和80%(HR 0.20;95%CI 0.10-0.37)。
临床怎么用
- 对携带BRCA1/2突变的新诊断晚期卵巢癌患者,无论手术类型、化疗反应或术后残存状态,均可考虑奥拉帕利维持治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In SOLO1, maintenance olaparib (300 mg twice daily) significantly improved progression-free survival (PFS) for patients with newly diagnosed BRCA1- and/or BRCA2-mutated advanced ovarian cancer compared with placebo (hazard ratio [HR], 0.30; 95% CI, 0.23 to 0.41; median not reached v 13.8 months). We investigated PFS in SOLO1 for subgroups of patients based on preselected baseline factors. PATIENTS AND METHODS: Investigator-assessed PFS subgroup analyses of SOLO1 included clinical response after platinum-based chemotherapy (complete [CR] or partial response [PR]), surgery type (upfront or interval surgery), disease status after surgery (residual or no gross residual disease), and BRCA mutation status (BRCA1 or BRCA2). Additionally, we evaluated PFS in patients with stage III disease who underwent upfront surgery and had no gross residual disease. We also report objective response rate. RESULTS: The risk of disease progression or death was reduced with olaparib compared with placebo by 69% (HR, 0.31; 95% CI, 0.21 to 0.46) and 63% (HR, 0.37; 95% CI, 0.24 to 0.58) in patients undergoing upfront or interval surgery; 56% (HR, 0.44; 95% CI, 0.25 to 0.77) and 67% (HR, 0.33; 95% CI, 0.23 to 0.46) in patients with residual or no residual disease after surgery; 66% (HR, 0.34; 95% CI, 0.24 to 0.47) and 69% in women with clinical CR or PR at baseline (HR, 0.31; 95% CI, 0.18 to 0.52); and 59% (HR, 0.41; 95% CI, 0.30 to 0.56) and 80% (HR 0.20; 95% CI, 0.10 to 0.37) in patients with a BRCA1 or BRCA2 mutation, respectively. CONCLUSION: Patients with newly diagnosed advanced ovarian cancer achieve substantial benefit from maintenance olaparib treatment regardless of baseline surgery outcome, response to chemotherapy, or BRCA mutation type.
引用
- DiSilvestro P, Colombo N, Scambia G, et al. Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial. J Clin Oncol. 2020. PMID: 32749942. doi:10.1200/JCO.20.00799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。